SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 23, 2015


MERIDIAN BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)

Ohio
  
0-14902
  
31-0888197
(State or other jurisdiction of incorporation)
  
(Commission File Number)
 
  
(IRS Employer Identification No. )


3471 River Hills Drive, Cincinnati, Ohio
  
45244
(Address of principal executive offices)
  
(Zip Code)

Registrant's telephone number, including area code
(513) 271-3700


 
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 ☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 ☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 2.02.                          Results of Operations and Financial Condition.
 
Reference is made to the press release of Meridian Bioscience, Inc. (the "Company") relating to the announcement of the Company's results of operations for the fiscal quarter and six months ended March 31, 2015. While the press release was issued on April 23, 2015, it was not filed previously on Form 8-K. A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
 
Item 9.01                          Financial Statements and Exhibits.

(d)            Exhibits
99.1            Press Release dated April 23, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
Date:  August 7, 2015
MERIDIAN BIOSCIENCE, INC.
 
By:  /s/ Melissa A. Lueke                                                                     
Melissa A. Lueke
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)